Meet the eHealthEBM+ Professional Team

 At eHealthEBM+, our team is composed of experts from diverse backgrounds in medicine, AI technology, genomics, and evidence-based healthcare. Together, we are dedicated to transforming the healthcare landscape by combining advanced technology with the latest in clinical research to improve patient outcomes and optimize care delivery. 

Dr. Sam Lee (fka: Zhengsheng Li, PhD, Former Surgeon) is a well-known expert and pioneering scientist in the field of evidence-based medicine (EBM), with more than 10 years of clinical experience as a general surgeon, including Shanghai Ruijin Hospital, more than 20 years of evidence-based medical research and consulting experience in the United States, and biomedical research experience and achievements in the United States and China. Dr. Lee received his Master of Surgery (MM) and Doctor of Surgery (PhD) degrees with honors from Shanghai Jiao Tong University School of Medicine. Two years later, in response to the U.S.-China Exchange Visiting Scholar Program, he was invited to the United States National Institutes of Health (NIH) for postdoctoral research. After completing his postdoctoral fellowship, he was awarded the NIH Research Fellowship and spent a full five years at the NIH as a research scholar, focusing on cancer, infectious diseases, and child and human development, using advanced genomics, genetics, and molecular cell biology techniques.

Dr. Lee's research was conducted at St. Johnson Children's Research Hospital. Jude Children's Research Hospital and the University of Tennessee Health Science Center, among others, continue to expand. In these institutions, he has used Whole Genome Sequencing, Total RNA Sequencing (RNA-seq), and its Genome-wide Association Study (GWAS), Phenotype-wide Association Study (PheWAS), and yeast genetics to study disease-related gene clusters, gene networks, and the effectiveness of anti-cancer drugs. His research achievements include curing patients with numerous complex and rare diseases, publishing numerous research papers, abstracts, and presentations, and co-creating a total RNA database of BXD mice on the UCSC Genome Browser with colleagues for sharing with scholars worldwide. In addition, Dr. Lee has spent his career training medical students and biomedical technologists in the United States and China.
 

The coronavirus crisis has starkly highlighted the need for more advanced health solutions and strategies in public health. During the coronavirus crisis, Dr. Lee learned about the outbreak in Wuhan from the beginning and volunteered to provide emergency information to several entities, including the United States and Chinese governments and the World Health Organization (WHO). With a strong sense of responsibility and a passion for improving global health, Dr. Lee is always looking for opportunities to contribute to public health. Motivated by this, Dr. Lee has been pursuing a Doctor of Hospital Management (DHA) degree in United States since 2023, with a focus on operational leadership and quantitative research in Hospital Administration and Medical. Through this project, he aims to enhance his knowledge, competencies and skills in healthcare management and public health engagement (KAS) in order to contribute to more effective healthcare operations and responses in future public health crises, while working to address some of the systemic deficiencies in the traditional healthcare system.
 

Based on his extensive clinical experience and long-term commitment to advanced biomedical research, Dr. Lee founded eHealthEBM+, Inc., registered in San Diego, California, United States. Here, he combines his expertise in surgery, cancer research, and genomics to lead evidence-based medicine research and consulting using AI-enabled evidence-based medicine. His focus is on providing personalized, data-driven, and holistic healthcare solutions to improve patient outcomes and minimize medical errors in hospitals.

Dr. Lee holds several certifications in the United States, including:

• Holistic Health Coach Certificate from Duke University
• Scientific Writing Certification from Stanford Medical School in California, United States
• United States accreditation in the practice of science for medical improvement from Harvard Medical School
• Clinical Operations Quality and Safety Certification from Harvard Medical School in United States

• Advanced Cardiac Life Support (ACLS) certification from Denver Graduate School of Medicine, Colorado, United States

 eHealthEBM+ is honored to appoint Professor Shufeng Zhou as its Honorary Chief Scientist. Professor Zhou is a globally renowned Chinese-American biomedical scientist with profound academic achievements and significant contributions to the industry. He has served as a New Drug Reviewer for the U.S. FDA, an expert committee member for the WHO, and a Fellow of the American Institute for Medical and Biological Engineering. He has published over 800 scientific papers with more than 50,000 citations and an H-index of 116, holding over 100 international and Chinese patents.

As a distinguished leader in biomedical research, Professor Zhou has made groundbreaking contributions to innovative drug development, including the invention of the small molecule drug Vadimezan for advanced lung cancer. He has also trained a large number of high-caliber professionals, advancing global medical development. His appointment will greatly enhance eHealthEBM+’s efforts in AI-driven evidence-based medicine, accelerating advancements in precision medicine and intelligent healthcare on a global scale. 

Professor Zhang Xinkai is a distinguished expert in the fields of psychiatry and clinical psychology in China. He currently serves as the Chief Medical Officer (CMO) for the East China region at eHealthEBM+ (MeiHua AI Evidence-Based Medicine).

Professor Zhang holds a Doctorate in Medicine and is a Chief Physician at the Shanghai Mental Health Center. He was the first doctoral graduate in psychiatry from Shanghai Jiao Tong University and is now a Professor of Psychiatry and Mental Health at Shanghai Jiao Tong University School of Medicine, where he also mentors graduate students. Additionally, he is the Chief Medical Scientist at the Shanghai Emotional Health Center and a Distinguished Professor in the Music Therapy Program at the Shanghai Conservatory of Music. Professor Zhang also heads the Shanghai Center for Clinical Diagnosis and Consultation of Mental Disorders and holds key positions in academic committees within the Chinese Mental Health Association and Music Therapy Society, making him a leading authority in psychological counseling and music therapy in China.

Born into a family with a legacy in psychiatry, Professor Zhang trained under Professor Zhang Mingyuan, the Chairman of the Chinese Psychiatric Association. With 40 years of experience in psychiatric and clinical psychology practice, teaching, and research, Professor Zhang has accumulated extensive clinical expertise. He specializes in providing personalized, holistic solutions for patients with psychiatric and psychological disorders. His groundbreaking “Integrated Solution for Emotional Disorders” has received widespread acclaim, ensuring comprehensive support for patients during both clinical treatment and psychological rehabilitation.

Professor Zhang is committed to integrating clinical practice with research and teaching while promoting mental health and professional training. He has led more than ten research projects and published over 30 academic papers in prestigious domestic and international journals, including studies such as “Psychological Risk Factors in Alzheimer’s Disease” and “Social and Psychological Risk Factors in Alzheimer’s Disease.” He has actively participated in international academic exchanges, contributing significantly to the advancement of the field.

He is also the author of several classic works, including Cognitive Behavioral Group Therapy for Anxiety, Depression, Fear, and Phobia and Clinical Training Manual for Music Therapists, which provide essential guidance for mental health and psychiatric treatment.

Since joining eHealthEBM+, Professor Zhang Xinkai has been dedicated to advancing the integration of AI technology with mental and psychological health. His efforts aim to bring more precise and efficient medical services and health management solutions to the East China region and beyond.

Professor Hua Zhang, PhD, as the company’s Honorary Co-Chairman and Chief Policy Advisor, plays a critical role in the company’s strategic development and policy-making. He is a seasoned expert in biotechnology and high-tech enterprise management, with over 20 years of extensive experience. Formerly serving as Vice President of a renowned biotech group affiliated with Peking University and managing multiple top technology departments, he brings deep management expertise and strategic vision to the company. Professor Zhang’s leadership and innovation capabilities provide strong support for the company’s expansion in high-tech fields and public relations development. His broad influence and academic contributions within the industry further solidify the company’s standing.

As Chief Policy Advisor for eHealthEBM+, Professor Zhang provides stable strategic and policy support for the company’s innovative development through his unique insights into policy and management, ensuring that eHealthEBM+ achieves its vision and mission of delivering global health solutions. 

Dr. Tao Cai, MD, PhD, as the company’s Honorary Director of Research and Chief Geneticist, plays an irreplaceable role in advancing the company’s research strategy and genomic innovation. With over 20 years of extensive experience in genomic medicine and genetics applications, he previously served as a researcher at the NIH, where he was awarded Honorary Retiree status. Dr. Cai has made groundbreaking achievements in key areas such as gene analysis, neurobiology, and novel gene research, laying a solid foundation for the company’s advancements in cutting-edge medical research and innovation.

Dr. Cai’s academic background and research accomplishments are highly regarded within the industry, with over 80 high-level academic papers published, which will bring the company broader international recognition. He actively participates in the F1000Prime academic committee and serves as an associate editor for several prestigious journals, including Journal of Translational Medicine, PLOS One, and BMC Medical Genomics. His involvement significantly enhances the company’s academic standing and research influence, ensuring the company remains at the forefront of genetics and genomic medicine. 

Dr. Shu Zhang, MD, as the company’s Honorary Chief Medical Officer for the United States region, plays a unique and essential role in elevating the standards and innovation of the company’s healthcare services in North America. Serving as a hospitalist at Banner Health and North Colorado Medical Center (NCMC), he specializes in diagnosing and treating complex and critical cases across a wide range of fields, including cardiovascular, respiratory, digestive, neurological, hematological, and musculoskeletal diseases. Dr. Zhang’s extensive experience in emergency medicine provides invaluable clinical expertise for the company, ensuring exceptional performance in critical care management.

Dr. Zhang’s specialized knowledge and deep understanding of acute and complex care make him an indispensable medical leader for the company in the North American healthcare market. His unique perspective and clinical skills not only enhance the quality of the company’s services but also help establish a leading position in complex disease management and emergency medicine. 

Dr. Yongping Zhao, MD, PhD, as the company’s Honorary Chief Medical Officer for the China region, plays an indispensable role in advancing the company’s research and clinical applications in men’s health. As Chief Physician at the Reproductive Medicine Center of Peking University People’s Hospital, Dr. Zhao has extensive expertise in andrology and reproductive medicine, particularly in areas such as assisted reproductive technology, male infertility, and urogenital infections. He not only holds key positions in numerous major medical committees in China but also brings significant influence in the fields of men’s health and reproductive medicine to the company.

Dr. Zhao’s leadership and professional skills ensure that the company’s clinical service quality in the Chinese market meets the highest standards. His multidisciplinary research and clinical experience provide invaluable support for the company’s medical innovations, significantly enhancing its academic standing and industry reputation in men’s health. Through Dr. Zhao’s professional guidance, the company has established and maintained a leading position in men’s health and reproductive medicine, offering scientifically rigorous healthcare services to clients. 

Dr. Simeon Zou, MD, PhD, as the company’s Chief Neurologist, plays an irreplaceable role in promoting clinical excellence and technological innovation in the neurology department. Serving as an attending neurologist at Deaconess Hospital, he specializes in the diagnosis and treatment of complex neurological diseases and is certified by the American Board of Psychiatry and Neurology (ABPN). Dr. Zou’s expertise spans multiple critical areas, including general neurology, electroencephalography (EEG), nerve conduction studies/electromyography (NCS/EMG), and intraoperative neurophysiological monitoring (IONM), ensuring the company’s leading position in neurological diagnostics and treatment.

Additionally, Dr. Zou serves as a clinical assistant professor at the Homer Stryker MD School of Medicine at Western Michigan University, contributing to medical education. With his extensive clinical experience in both China and the United States, Dr. Zou’s knowledge and skills provide unique support for the company in managing complex neurological diseases and precision treatment, solidifying its leading position in the field of neurology. 

As the company’s U.S. Medical Education Specialist, Dr. Matthew Pullen plays a key role in advancing the company’s international medical education and training efforts. He completes his medical education and residency training at the University of Tennessee Health Science Center in Memphis and specializes in infectious disease and international medicine at the University of Minnesota. Currently, his research focuses on novel coronavirus technology and H4 bacterial genome transmission. During his fellowship training, Dr. Pullen’s research targets tuberculosis, cryptococcal meningitis, and the global impact of COVID-19.

Dr. Pullen also receives the prestigious NIH Fogarty Global Health Fellowship, enabling him to conduct a tuberculosis genomic sequencing project in Uganda while providing clinical consultation and medical education lectures. His academic background and international research experience provide the company with irreplaceable expertise, maintaining the company’s leading position in global health education and significantly enhancing its international influence.
 

As the company’s Chief Ophthalmologist, Dr. Caihong Zhu plays a crucial role in elevating the quality of the company’s ophthalmology services and advancing ophthalmic technology. Since 1995, Dr. Zhu has accumulated extensive clinical experience at Ruijin Hospital, with deep expertise in treating retinal diseases, posterior capsular opacification, angle-closure glaucoma, and macular conditions using laser therapy. Her proficiency in retinal angiography provides strong support for the company’s precision diagnostics.

Dr. Zhu has published over 30 professional papers and co-authored several academic books. She is also active in the field, serving as a member of the Shanghai Ophthalmology Branch of the Chinese Medical Association and the Retinal Disease Group. Her professional contributions and academic influence not only reinforce the company’s technological leadership but also enhance its reputation in ophthalmology. Dr. Zhu’s involvement ensures that the company continues to provide scientifically rigorous and technologically advanced vision health management services. 

As the Director of the company’s Traditional Chinese Medicine (TCM) and Acupuncture departments, Dr. Jian Yan plays an irreplaceable role in enhancing the quality of the company’s TCM and acupuncture services and driving technological innovation. He is certified by the National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM) as a TCM practitioner and acupuncturist, with a solid academic background and extensive clinical experience, including a PhD in TCM internal medicine from Sun Yat-sen Medical University, specializing in oncology and infectious disease. Dr. Yan holds positions as an attending physician in several renowned TCM and acupuncture centers, gaining profound clinical experience, especially in treating complex conditions such as cancer, pain, arthritis, and immune disorders.

Dr. Yan’s expertise and clinical practice provide invaluable support for the company’s precision medical services, ensuring its leading position in TCM and acupuncture therapy. Additionally, as an active member of various academic and professional committees, he enjoys high recognition within the industry and publishes over 20 academic papers in SCI journals. His contributions to integrative medicine not only reinforce the company’s reputation in the global health management market but also provide valuable insights and innovative capabilities. 

As the company’s Director of Integrative Medicine, Dr. Yanzhao Wei plays a unique and important role in enhancing the company’s integrative medicine services. A senior expert at Guoyitang, he has over 30 years of extensive clinical experience, particularly in treating common and chronic conditions such as shoulder and neck pain, lumbar disc herniation, rheumatoid arthritis, ankylosing spondylitis, osteoporosis, and skin wound repair. Dr. Wei’s unique insights and outstanding results in integrative treatment methods are highly praised by patients, significantly improving their recovery outcomes.

Dr. Wei’s expertise and vast experience provide strong support for the company’s precision medical services, maintaining its leading position in the field of integrative medicine. His involvement not only strengthens the company’s technical advantages but also elevates its reputation in the health management market. 

 As the company’s Director of Obstetrics and Gynecology, Dr. Hong Xu plays an irreplaceable role in enhancing the company’s OB/GYN services and driving technological innovation. She graduated from Henan University and currently serves as an Associate Chief Physician at Weinan Second People’s Hospital, with 36 years of extensive clinical experience in obstetrics and gynecology. Dr. Xu possesses deep expertise in hysteroscopy and laparoscopy combined procedures, as well as infertility treatment, providing strong support for the company’s precision medical services.

Dr. Xu’s extensive experience and professional skills bring significant clinical advantages to the company in the OB/GYN field. Her involvement ensures that the company maintains a leading position in OB/GYN medical services, delivering high-quality and scientifically rigorous care to patients.